0 Items
Select Page

Tick-Borne Encephalitis

Tick-borne encephalitis virus (TBEV) causes 13,000 cases of human meningitis and encephalitis annually. Mortality varies depending on the sub-type, but long-term neuropsychiatric disorders can occur in a significant proportion of patients.

The Native Antigen Company offers recombinant TBEV proteins developed from our proprietary mammalian expression system.

TBEV Background

Tick-borne Encephalitis virus (TBEV) is primarily transmitted through the bite of infected hard ticks, of the family Ixodidae. Small rodents are the primary hosts for TBEV, with humans acting as accidental hosts. The virus can also be transmitted to humans through unpasteurized milk in areas where TBEV is prevalent (CDC).

TBEV is a neurotrophic virus that causes tick-born encephalitis (TBE) in humans, affecting the central nervous system (CNS). TBE is endemic in many parts of Europe, China, Mongolia and the Russian Federation, and is the most common tick-borne CNS infection in these areas (WHO). Three subtypes of TBEV have been recognised that cause TBR, which are European, Far-Eastern and Siberian.

TBEV infection is asymptomatic in most cases with some individuals presenting with influenza-like symptoms. In symptomatic cases, TBEV infection typically presents as meningitis, encephalitis or meningoencephalitis. A high percentage of acute TBE cases may also develop post-encephalitic syndrome with long-lasting neuropsychiatric symptoms or neurological dysfunction (Bogovic, P).

Diagnosis of TBE infection is primarily based on clinical presentation and serological testing for TBEV-specific IgM and IgG antibodies in patient sera and cerebrospinal fluid. There is no anti-viral treatment for TBEV. However, several effective vaccines for TBEV are currently available which are based on European and Far-Eastern strains of the virus (WHO).

Tick-Borne Encephalitis Antigens

The Native Antigen Company prepares recombinant TBEV proteins in its proprietary mammalian cell expression system, including highly pure NS1 protein, in its glycosylated and predominantly hexameric format.

Tick-Borne Encephalitis Antibodies

The Native Antigen Company is pleased to offer a full panel of monoclonal antibodies to TBEV antigens, which are suitable for the development of specific immunoassays. These antibodies have been tested against our renowned mammalian-expressed, recombinant proteins, and are suitable for use in both ELISA and Western blot applications.

 

Tick-Borne Encephalitis Immunoassays

We are pleased to offer ELISA assays for the detection of antibody response (IgG and IgM) to Tick-borne encephalitis virus. These assays are suitable for use in laboratory research and development activities and vaccine research studies.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Using Adenoviruses to Fight Cancer

In the second of a 2-part series, we discuss how adenoviruses are being developed to treat cancer and some of the hurdles these platforms face from our own immune systems. Curing cancer is one of the biggest challenges of the 21st century. Our knowledge of cancer’s...

New Immunofluorescence Data for our CMV, Yellow Fever and Ebola Antibodies

In September 2018 The Native Antigen Company and Virology Research Services (VRS) were awarded the Medical Research Council (Proximity to Discovery Award for Knowledge Exchange) to test a large panel of our viral antibodies in immunofluorescence applications. This...

Why are ticks such good vectors of pathogens?

In this blog, Professor Patricia Nuttall discusses what makes ticks such effective vectors of pathogens and how we might prevent the spread of tick-borne diseases. About Patrica Nuttall Pat Nuttall is Emeritus Professor of Arbovirology in the Department of Zoology,...

Dengue in 2019

What's going on with dengue? Dengue virus (DENV) has been in the news a lot recently. The number of reported cases continues to climb year-on-year and 2019 has been especially bad. Rio de Janeiro has seen a 45% increase in dengue cases in the first two months of 2019...

Zika Prevalence in Suriname – an insight into assay cross-reactivity

A recent study published by Langerak et al tested for the seroprevalence of Zika virus in Suriname populations and evaluated the comparative effectiveness of using a commercial ELISA and a standard Virus Neutralisation Assay. Here we discuss the study, its results,...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

15 + 7 =

Live Customer Feedback